Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Molecular signature of Epstein-Barr virus infection in MS brain lesions.

Moreno MA, Or-Geva N, Aftab BT, Khanna R, Croze E, Steinman L, Han MH.

Neurol Neuroimmunol Neuroinflamm. 2018 Jun 7;5(4):e466. doi: 10.1212/NXI.0000000000000466. eCollection 2018 Jul.

2.

Persistency of Neutralizing Anti-Interferon-β Antibodies in Patients with Multiple Sclerosis Treated with Subcutaneous Interferon-β Depends on Antibody Titers, IgG Subclasses, and Affinity Maturation.

Dujmovic I, Hegen H, Paz P, Croze E, Deisenhammer F.

J Interferon Cytokine Res. 2017 Jul;37(7):317-324. doi: 10.1089/jir.2016.0080. Epub 2017 Apr 18.

PMID:
28418769
3.

Induction of a unique isoform of the NCOA7 oxidation resistance gene by interferon β-1b.

Yu L, Croze E, Yamaguchi KD, Tran T, Reder AT, Litvak V, Volkert MR.

J Interferon Cytokine Res. 2015 Mar;35(3):186-99. doi: 10.1089/jir.2014.0115. Epub 2014 Oct 20.

4.

Type I Interferon Receptor Expression in Human Pancreatic and Periampullary Cancer Tissue.

Booy S, Hofland LJ, Waaijers AM, Croze E, van Koetsveld PM, de Vogel L, Biermann K, van Eijck CH.

Pancreas. 2015 Jan;44(1):99-105. doi: 10.1097/MPA.0000000000000202.

PMID:
25072284
5.

Interleukin 17F level and interferon β response in patients with multiple sclerosis.

Hartung HP, Steinman L, Goodin DS, Comi G, Cook S, Filippi M, O'Connor P, Jeffery DR, Kappos L, Axtell R, Knappertz V, Bogumil T, Schwenke S, Croze E, Sandbrink R, Pohl C.

JAMA Neurol. 2013 Aug;70(8):1017-21. doi: 10.1001/jamaneurol.2013.192.

6.

Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis.

Croze E, Yamaguchi KD, Knappertz V, Reder AT, Salamon H.

Pharmacogenomics J. 2013 Oct;13(5):443-51. doi: 10.1038/tpj.2012.27. Epub 2012 Jun 19.

7.

Interferon β-1b and glatiramer acetate effects on permanent black hole evolution.

Filippi M, Rocca MA, Camesasca F, Cook S, O'Connor P, Arnason BG, Kappos L, Goodin D, Jeffery D, Hartung HP, Comi G, Wolinsky JS, Bogumil T, Pohl C, Beckmann K, Sandbrink R, Croze E, Brown C, Desimone TM, Arnold DL, Cutter G, Knappertz V.

Neurology. 2011 Apr 5;76(14):1222-8. doi: 10.1212/WNL.0b013e3182143577.

8.

Effects of interferons α/β on the proliferation of human micro- and macrovascular endothelial cells.

Erdmann J, Vitale G, van Koetsveld PM, Croze E, Sprij-Mooij DM, Hofland LJ, van Eijck CH.

J Interferon Cytokine Res. 2011 May;31(5):451-8. doi: 10.1089/jir.2009.0103. Epub 2011 Mar 1.

PMID:
21361792
9.

Interferonβ-1b Induces the Expression of RGS1 a Negative Regulator of G-Protein Signaling.

Tran T, Paz P, Velichko S, Cifrese J, Belur P, Yamaguchi KD, Ku K, Mirshahpanah P, Reder AT, Croze E.

Int J Cell Biol. 2010;2010:529376. doi: 10.1155/2010/529376. Epub 2011 Jan 17.

10.

Differential gene expression and translational approaches to identify biomarkers of interferon beta activity in multiple sclerosis.

Croze E.

J Interferon Cytokine Res. 2010 Oct;30(10):743-9. doi: 10.1089/jir.2010.0022. Review.

PMID:
20874251
11.

STAT-phosphorylation-independent induction of interferon regulatory factor-9 by interferon-beta.

Rani MR, Croze E, Wei T, Shrock J, Josyula A, Kalvakolanu DV, Ransohoff RM.

J Interferon Cytokine Res. 2010 Mar;30(3):163-70. doi: 10.1089/jir.2009.0032.

12.

Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing.

Bernasconi E, Favre L, Maillard MH, Bachmann D, Pythoud C, Bouzourene H, Croze E, Velichko S, Parkinson J, Michetti P, Velin D.

Inflamm Bowel Dis. 2010 Mar;16(3):428-41. doi: 10.1002/ibd.21072.

PMID:
19639560
13.

Inhibition of neurosphere proliferation by IFNgamma but not IFNbeta is coupled to neuronal differentiation.

Lum M, Croze E, Wagner C, McLenachan S, Mitrovic B, Turnley AM.

J Neuroimmunol. 2009 Jan 3;206(1-2):32-8. doi: 10.1016/j.jneuroim.2008.10.009. Epub 2008 Nov 22.

PMID:
19027965
14.

IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.

Reder AT, Velichko S, Yamaguchi KD, Hamamcioglu K, Ku K, Beekman J, Wagner TC, Perez HD, Salamon H, Croze E.

J Interferon Cytokine Res. 2008 May;28(5):317-31. doi: 10.1089/jir.2007.0131.

PMID:
18547162
15.

IFN-beta-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions.

Yamaguchi KD, Ruderman DL, Croze E, Wagner TC, Velichko S, Reder AT, Salamon H.

J Neuroimmunol. 2008 Mar;195(1-2):116-20. doi: 10.1016/j.jneuroim.2007.12.007. Epub 2008 Feb 14.

PMID:
18279974
16.

Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis.

Sainathan SK, Hanna EM, Gong Q, Bishnupuri KS, Luo Q, Colonna M, White FV, Croze E, Houchen C, Anant S, Dieckgraefe BK.

Inflamm Bowel Dis. 2008 Jan;14(1):88-99.

17.

Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors.

Vitale G, van Eijck CH, van Koetsveld Ing PM, Erdmann JI, Speel EJ, van der Wansem Ing K, Mooij DM, Colao A, Lombardi G, Croze E, Lamberts SW, Hofland LJ.

Ann Surg. 2007 Aug;246(2):259-68.

18.

Interferon-beta attenuates angiotensin II-accelerated atherosclerosis and vascular remodeling in apolipoprotein E deficient mice.

Zhang LN, Velichko S, Vincelette J, Fitch RM, Vergona R, Sullivan ME, Croze E, Wang YX.

Atherosclerosis. 2008 Mar;197(1):204-11. Epub 2007 Apr 26.

PMID:
17466308
19.

Antiviral and myocyte protective effects of murine interferon-beta and -{alpha}2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice.

Wang YX, da Cunha V, Vincelette J, White K, Velichko S, Xu Y, Gross C, Fitch RM, Halks-Miller M, Larsen BR, Yajima T, Knowlton KU, Vergona R, Sullivan ME, Croze E.

Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H69-76. Epub 2007 Apr 13.

20.

Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth.

van Koetsveld PM, Vitale G, de Herder WW, Feelders RA, van der Wansem K, Waaijers M, van Eijck CH, Speel EJ, Croze E, van der Lely AJ, Lamberts SW, Hofland LJ.

J Clin Endocrinol Metab. 2006 Nov;91(11):4537-43. Epub 2006 Aug 15.

PMID:
16912135
21.

IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro.

Vitale G, de Herder WW, van Koetsveld PM, Waaijers M, Schoordijk W, Croze E, Colao A, Lamberts SW, Hofland LJ.

Cancer Res. 2006 Jan 1;66(1):554-62.

22.

Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors.

Wagner TC, Velichko S, Chesney SK, Biroc S, Harde D, Vogel D, Croze E.

Int J Cancer. 2004 Aug 10;111(1):32-42.

23.

SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor.

Kumar KG, Tang W, Ravindranath AK, Clark WA, Croze E, Fuchs SY.

EMBO J. 2003 Oct 15;22(20):5480-90.

25.

Interferon signaling is dependent on specific tyrosines located within the intracellular domain of IFNAR2c. Expression of IFNAR2c tyrosine mutants in U5A cells.

Wagner TC, Velichko S, Vogel D, Rani MR, Leung S, Ransohoff RM, Stark GR, Perez HD, Croze E.

J Biol Chem. 2002 Jan 11;277(2):1493-9. Epub 2001 Oct 26.

26.
27.

Receptor for activated C-kinase (RACK-1), a WD motif-containing protein, specifically associates with the human type I IFN receptor.

Croze E, Usacheva A, Asarnow D, Minshall RD, Perez HD, Colamonici O.

J Immunol. 2000 Nov 1;165(9):5127-32.

28.

Development of an Immunofluorometric, High-Capacity, Cell-Based Assay for the Measurement of Human Type I and Type II Interferons.

Trinh L, Ziegler R, Watling D, Snider RM, Croze E.

J Biomol Screen. 1999;4(1):33-37.

PMID:
10838410
29.

Role of the intracellular domain of the human type I interferon receptor 2 chain (IFNAR2c) in interferon signaling. Expression of IFNAR2c truncation mutants in U5A cells.

Russell-Harde D, Wagner TC, Rani MR, Vogel D, Colamonici O, Ransohoff RM, Majchrzak B, Fish E, Perez HD, Croze E.

J Biol Chem. 2000 Aug 4;275(31):23981-5.

30.
32.

Differential effects of IFN-beta1b on the proliferation of human vascular smooth muscle and endothelial cells.

Mintzer RJ, Croze E, Rubanyi GM, Johns A.

J Interferon Cytokine Res. 1998 Nov;18(11):939-45.

PMID:
9858315
33.
34.

Interferon-beta is a potent promoter of nerve growth factor production by astrocytes.

Boutros T, Croze E, Yong VW.

J Neurochem. 1997 Sep;69(3):939-46.

35.

The short form of the interferon alpha/beta receptor chain 2 acts as a dominant negative for type I interferon action.

Pfeffer LM, Basu L, Pfeffer SR, Yang CH, Murti A, Russell-Harde D, Croze E.

J Biol Chem. 1997 Apr 25;272(17):11002-5.

36.

The human type I interferon receptor. Identification of the interferon beta-specific receptor-associated phosphoprotein.

Croze E, Russell-Harde D, Wagner TC, Pu H, Pfeffer LM, Perez HD.

J Biol Chem. 1996 Dec 27;271(52):33165-8.

37.

Human renal cancers resistant to IFN's antiproliferative action exhibit sensitivity to IFN's gene-inducing and antiviral actions.

Pfeffer LM, Wang C, Constantinescu SN, Croze E, Blatt LM, Albino AP, Nanus DM.

J Urol. 1996 Nov;156(5):1867-71.

PMID:
8863634
38.

Direct association of STAT3 with the IFNAR-1 chain of the human type I interferon receptor.

Yang CH, Shi W, Basu L, Murti A, Constantinescu SN, Blatt L, Croze E, Mullersman JE, Pfeffer LM.

J Biol Chem. 1996 Apr 5;271(14):8057-61.

39.

Expression and signaling specificity of the IFNAR chain of the type I interferon receptor complex.

Constantinescu SN, Croze E, Murti A, Wang C, Basu L, Hollander D, Russell-Harde D, Betts M, Garcia-Martinez V, Mullersman JE, Pfeffer LM.

Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10487-91.

40.

Reconstitution of a high affinity binding site for type I interferons.

Russell-Harde D, Pu H, Betts M, Harkins RN, Perez HD, Croze E.

J Biol Chem. 1995 Nov 3;270(44):26033-6.

41.

Homology model of human interferon-alpha 8 and its receptor complex.

Seto MH, Harkins RN, Adler M, Whitlow M, Church WB, Croze E.

Protein Sci. 1995 Apr;4(4):655-70.

42.

The use of Zwittergent 3-14 in the purification of recombinant human interferon-beta Ser17 (Betaseron).

Russell-Harde D, Knauf M, Croze E.

J Interferon Cytokine Res. 1995 Jan;15(1):31-7.

PMID:
7648432
43.

Role of interferon alpha/beta receptor chain 1 in the structure and transmembrane signaling of the interferon alpha/beta receptor complex.

Constantinescu SN, Croze E, Wang C, Murti A, Basu L, Mullersman JE, Pfeffer LM.

Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9602-6.

44.

A specific radioimmunoassay for the measurement of gadoteridol, a contrast agent for magnetic resonance imaging in biological fluids.

Ogan MD, Reiss AC, Croze EM, Jagoda EM, Stouffer BC, Mantha S, Tsay HM, Yost FJ, Tu JI.

J Pharm Sci. 1993 May;82(5):475-9.

PMID:
8360824
45.
46.

Immunocytochemical localization of class I H-2 histocompatibility antigens of mouse liver.

Croze EM, Morré DJ.

Eur J Cell Biol. 1984 Sep;35(1):90-8.

PMID:
6333341
47.
48.

Monodehydroascorbate as an electron acceptor for NADH reduction by coated vesicle and Golgi apparatus fractions of rat liver.

Sun I, Morré DJ, Crane FL, Safranski K, Croze EM.

Biochim Biophys Acta. 1984 Feb 14;797(2):266-75.

PMID:
6141808
49.

Distribution of clathrin and spiny-coated vesicles on membranes within mature Golgi apparatus elements of mouse liver.

Croze EM, Morré DJ, Morré DM, Kartenbeck J, Franke WW.

Eur J Cell Biol. 1982 Aug;28(1):130-8. No abstract available.

PMID:
6127212
50.

Albumin secreted by rat liver bypasses Golgi apparatus cisternae.

Franz CP, Croze EM, Morré DJ, Schreiber G.

Biochim Biophys Acta. 1981 Dec 18;678(3):395-402.

PMID:
7317458

Supplemental Content

Support Center